510(k) Report

510(k) · Cleared

Cleared

Optilite® Freelite Mx Kappa Free Kit; Optilite® Freelite Mx Lambda Free Kit

K250549510(k) TraditionalCleared May 23, 202587-day reviewClass II21 CFR 866.5550

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

The Binding Site Group, Ltd. · DFH Kappa, Antigen, Antiserum, Control

Cleared on May 23, 2025 as substantially equivalent to K040009 (The Binding Site, Ltd., 2004) after an 87-day review. Its family tree reaches back 1 generation to 2004.

Decided
May 23, 2025
Review
87 days
Class
Class II
Product code
DFH
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K040009 (2004). No later device cites it as a predicate yet.

K040009 · Freelite Human Kappa and Lambda Kits · The Binding Site, Ltd. · 2004200020052010201520202025
  1. Root · 1 generation backK040009 Freelite Human Kappa and Lambda KitsThe Binding Site, Ltd. · 2004
  2. This deviceK250549 Optilite® Freelite Mx Kappa Free Kit; Optilite® Freelite Mx Lambda…The Binding Site Group, Ltd. · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K040009Freelite Human Kappa and Lambda KitsThe Binding Site, Ltd.2004—
0 (this device)K250549Optilite® Freelite Mx Kappa Free Kit; Optilite® Freelite Mx Lambda Free KitThe Binding Site Group, Ltd.2025—
FIG. 1 — Lineage of K250549, 2004–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DFH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DFH device

  1. #1 K253358 Diazyme Human Kappa (k) Free Light Chain…score 10.5 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K040009Freelite Human Kappa and Lambda Kits
Summary page 6
…Page 2 of 10 3 PREDICATE DEVICES AND 510(k) NUMBERS Freelite® Human Kappa Free Kit for use on the Siemens BN™II - K040009 Freelite® Human Lambda Free Kit for use on the Siemens BN™II - K040009 4 DEVICE DESCRIPTION 4.1 Test Principle No…
The Binding Site, Ltd.2004—

Also cleared against K040009: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • 2 other devices also cite its predicate K040009.

How does its category compare?

All DFH devices

DFH Kappa, Antigen, Antiserum, Control: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · DFH

2in 2025

2007: 22008: 12009: 12013: 12015: 12016: 12017: 12018: 32019: 12021: 22022: 42024: 22025: 2
2007high 4 (2022) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DFH

340in 2022

2018: 90 days median2022: 340 days median
2007high 340 (2022) · low 90 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DFH

1in 2020

2020: 1
2007high 1 (2020) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DFH

10in 2025

2017: 12019: 42021: 12022: 112023: 32024: 132025: 10
2007high 13 (2024) · low 0 (2007)2025

MAUDE reports naming product code DFH, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20081—00
20091—00
20100—00
20110—00
20120—00
20131—00
20140—00
20151—00
20161—00
20171—01
201839000
20191—04
20200—10
20212—01
20224340011
20230—03
20242—013
20252—010
20260—0—

What is it indicated for?

Optilite® Freelite Mx Kappa Free Kit: The Optilite Freelite Mx Kappa Free Kit is intended for the quantitative in vitro measurement of Kappa free light chains in serum and urine using the Binding Site Optilite analyser. Measurement of free light chains in serum and urine aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenström’s macroglobulinaemia, AL amyloidosis, light chain deposition disease and connective tissue…

Read the full statement (214 words)

Optilite® Freelite Mx Kappa Free Kit:

The Optilite Freelite Mx Kappa Free Kit is intended for the quantitative in vitro measurement of Kappa free light chains in serum and urine using the Binding Site Optilite analyser. Measurement of free light chains in serum and urine aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenström’s macroglobulinaemia, AL amyloidosis, light chain deposition disease and connective tissue diseases such as systemic lupus erythematosus (SLE); and in serum aids in the evaluation of monoclonal gammopathy of undetermined significance (MGUS). Results of the free light chain measurements should always be interpreted in conjunction with other laboratory and clinical findings.

Optilite® Freelite Mx Lambda Free Kit:

The Optilite Freelite Mx Lambda Free Kit is intended for the quantitative in vitro measurement of Lambda free light chains in serum and urine using the Binding Site Optilite analyser. Measurement of free light chains in serum and urine aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenström’s macroglobulinaemia, AL amyloidosis, light chain deposition disease and connective tissue diseases such as systemic lupus erythematosus (SLE); and in serum aids in the evaluation of monoclonal gammopathy of undetermined significance (MGUS). Results of the free light chain measurements should always be interpreted in conjunction with other laboratory and clinical findings.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K250549: Optilite® Freelite Mx Kappa Free Kit; Optilite® Freelite Mx Lambda Free Kit.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K250549

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026